KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
The effect of doxepin 3 mg on sleep latency: a pooled analysis of two phase 3 trials. PMID 40229607 · Sleep Breath · 2025-Apr-14 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Design of a randomised, placebo-controlled, double-blind multicentre study assessing the effect of colchicine on the incidence of knee or hip replacements in symptomatic knee or hip osteoarthritis: the ECHO trial. PMID 40228852 · BMJ Open · 2025-Apr-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial. PMID 40222976 · Signal Transduct Target Ther · 2025-Apr-14 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. PMID 40086437 · Cancer Cell · 2025-Apr-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy. PMID 40220155 · J Neurol · 2025-Apr-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial. PMID 40158525 · Lancet · 2025-Apr-12 The trial is an oncology screening study comparing non-drug interventions (colonoscopy vs. faecal immunochemical test). The primary endpoint is colorectal cancer mortality at 10 years, which is a binary outcome (risk difference/RR), not a time-to-event endpoint with survival analysis (Kaplan-Meier or HR). No drug intervention is present. Therefore, it does not meet the criteria for a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Tadalafil on cardiac function and left ventricular dimensions in Duchenne muscular dystrophy: safety and cardiac MRI substudy results from a randomized, placebo-controlled trial. PMID 40217158 · BMC Cardiovasc Disord · 2025-Apr-11 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Corrigendum to "Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study" [Vaccine (38) (2020) 5194-5201]. PMID 39999539 · Vaccine · 2025-Apr-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study. PMID 40211191 · BMC Cancer · 2025-Apr-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. PMID 40162636 · N Engl J Med · 2025-Apr-10 The trial is a Phase III randomized study with a drug intervention and time-to-event endpoint. However, the endpoints are management of cancer-associated venous thromboembolism (a complication) and bleeding (safety), not a primary or key secondary oncologic efficacy endpoint (like OS, PFS, DFS). Therefore, it does not meet the criteria for an oncology efficacy trial for KM digitization.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion. PMID 39908448 · N Engl J Med · 2025-Apr-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial. PMID 39761503 · J Clin Oncol · 2025-Apr-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study. PMID 39656830 · Inflamm Bowel Dis · 2025-Apr-10 The study is a randomized Phase 2b/3 trial with a drug intervention (filgotinib) and is an original research report. However, it is not an oncology study; it investigates ulcerative colitis. Furthermore, the primary endpoints are biomarker changes and clinical scores, not time-to-event endpoints like OS, PFS, etc. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. PMID 39652826 · Blood · 2025-Apr-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. PMID 39652594 · J Clin Oncol · 2025-Apr-10 The record describes a randomized trial with a time-to-event endpoint (PFS) and a drug intervention, which meets most criteria. However, the phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, publication types, or deterministic review). The deterministic review flagged 'phase3_evidence_unclear' due to lack of explicit Phase III evidence in PubMed metadata. Since the phase cannot be established from the provided information, the trial is ineligible for the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis. PMID 39018016 · Inflamm Bowel Dis · 2025-Apr-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Similar Efficacy of Mesalazine in Adult and Older Adult Ulcerative Colitis Patients: Post Hoc Analysis of a Randomized Noninferiority Trial of 1600 mg vs 400 mg Tablets. PMID 38902993 · Inflamm Bowel Dis · 2025-Apr-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. PMID 38899786 · Inflamm Bowel Dis · 2025-Apr-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Trusted health system implementation strategies to increase vaccination (TRUE SYNERGI): a stepped-wedge cluster randomized trial to reduce HPV-related cancers. PMID 40205591 · BMC Public Health · 2025-Apr-09 This is a protocol for an implementation science study (stepped-wedge cluster randomized trial) testing strategies to increase HPV vaccination rates in primary care settings. While oncology-related (prevention of HPV-related cancers), it does not meet the core eligibility criteria: it is not a drug-containing intervention (vaccine is preventive, not therapeutic), it is a protocol without results, and the primary endpoint is not a time-to-event efficacy outcome (e.g., OS, PFS, DFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
"There's a lot of unknowns": a thematic analysis of the experiences of young adults with cancer who died during a psychosocial intervention trial. PMID 40205419 · BMC Palliat Care · 2025-Apr-09 The record describes a qualitative thematic analysis of patient experiences from a psychosocial intervention RCT. While it is an oncology RCT involving humans, it fails eligibility because: 1) The intervention is psychosocial, not drug-containing. 2) There is no time-to-event efficacy endpoint (e.g., OS, PFS, KM, HR). 3) The report type is a secondary/subgroup qualitative analysis, not the primary or definitive result of a Phase III drug trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Epidemiological Analysis of Obesity-related co-morbidities and mortality among post- menopausal women diagnosed with endometrial cancer: A Randomized Controlled Trial. PMID 40297687 · Res Sq · 2025-Apr-08 Study is an epidemiological analysis of comorbidities and mortality in endometrial cancer patients from the WHI, but does not involve a drug intervention as a key component. While it uses time-to-event methodology (Cox regression), it fails the core requirement of having a drug-containing intervention. The randomized trial nature refers to the WHI trial structure, but the analysis is observational within that context. Phase information is not explicitly provided.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SMALL: open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer-protocol for a phase III randomised multicentre trial. PMID 40204306 · BMJ Open · 2025-Apr-08 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Topical tacrolimus for the amelioration of breast cancer-related lymphedema (TACLE Trial): a study protocol for a randomized, double-blind, placebo-controlled phase II/III trial. PMID 40200322 · Trials · 2025-Apr-08 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial. PMID 40200187 · BMC Cancer · 2025-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial. PMID 40199888 · Nat Commun · 2025-Apr-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial. PMID 40199609 · J Immunother Cancer · 2025-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effectiveness of Stromal Vascular Fraction (SVF) and Platelet-Rich Plasma (PRP) in Patients With Knee Osteoarthritis: Protocol for a Phase 3, Prospective, Randomized, Controlled, Multicenter Study (SPOST Study). PMID 40198111 · JMIR Res Protoc · 2025-Apr-08 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update. PMID 39883948 · Blood Adv · 2025-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study. PMID 39801286 · Mod Rheumatol · 2025-Apr-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Laboratory markers predicting tofacitinib efficacy in Japanese patients with rheumatoid arthritis: A pooled analysis of Phase 2/3 randomised controlled clinical trials. PMID 39657989 · Mod Rheumatol · 2025-Apr-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4. PMID 39506562 · Mod Rheumatol · 2025-Apr-08 The record describes a randomized, Phase 3 trial of a drug (filgotinib) in humans, but the disease is rheumatoid arthritis, which is not oncology. Furthermore, the primary endpoint is not a time-to-event efficacy endpoint (it reports safety and clinical remission).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV. PMID 40197415 · AIDS Res Ther · 2025-Apr-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy, symptom control and optional supplemental jejunal feeding, on quality of life in patients with pancreatic cancer: a randomised controlled trial protocol. PMID 40197383 · Nutr J · 2025-Apr-07 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Reirradiation based on diffusion-weighted magnetic resonance imaging-guided dose- painting for locally advanced recurrent nasopharyngeal carcinoma: a phase 2 randomized controlled trial. PMID 40197313 · BMC Cancer · 2025-Apr-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Digital Health Intervention to Reduce Malnutrition Among Individuals With Gastrointestinal Cancer Receiving Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy: Feasibility, Acceptability, and Usability Trial. PMID 40194318 · JMIR Cancer · 2025-Apr-07 This is a single-arm feasibility study of a digital health intervention for malnutrition in GI cancer patients, not a randomized Phase III trial with a drug intervention and a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia. PMID 39815637 · Jpn J Clin Oncol · 2025-Apr-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113. PMID 39775866 · Jpn J Clin Oncol · 2025-Apr-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4+ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial. PMID 40333248 · Vaccines (Basel) · 2025-Apr-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Support for young people who are distressed by hearing voices: protocol for an uncontrolled feasibility evaluation of a psychological intervention package delivered within secondary schools (the ECHOES study). PMID 40186222 · Pilot Feasibility Stud · 2025-Apr-04 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). PMID 40186126 · BMC Cancer · 2025-Apr-04 The publication is a clinical trial protocol for a Phase III randomized trial comparing a drug (177Lu-edotreotide) to another drug (everolimus) with a primary time-to-event efficacy endpoint (PFS). However, it does not contain results; it is a protocol description. Therefore, it is not an original formal-result report and is excluded.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. PMID 40168091 · J Crohns Colitis · 2025-Apr-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults. PMID 40333267 · Vaccines (Basel) · 2025-Apr-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of RSV Prevention in Infancy on Prevalence of Asthma Among 9-14-Year-old Native American Children in the Southwest United States. PMID 40208934 · Pediatr Infect Dis J · 2025-Apr-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Alteplase for Posterior Circulation Ischemic Stroke at 4.5 to 24 Hours. PMID 40174223 · N Engl J Med · 2025-Apr-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. PMID 39602624 · N Engl J Med · 2025-Apr-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Gain-Framed Text Messages and Nicotine Replacement Therapy for Smoking Cessation Among Lung Cancer Screening Patients: A Brief Report of a Pilot Randomized Controlled Trial. PMID 40283767 · Int J Environ Res Public Health · 2025-Apr-02 The study is an oncology randomized controlled trial but is a pilot study (not Phase III or definitive) and the intervention (smoking cessation with NRT) is not a drug treatment for the malignancy itself; it lacks a primary time-to-event efficacy endpoint for cancer.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Wise or wide (WoW) study protocol: a national, multicentre, prospective, randomised and controlled, parallel group, non-inferiority study to compare single-staged versus two-staged excisions of thin invasive (≤1.0 mm) melanoma. PMID 40180392 · BMJ Open · 2025-Apr-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effectiveness and safety of shortened intensive treatment for children with tuberculous meningitis (SURE): a protocol for a phase 3 randomised controlled trial evaluating 6 months of antituberculosis therapy and 8 weeks of aspirin in Asian and African children with tuberculous meningitis. PMID 40180374 · BMJ Open · 2025-Apr-02 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Feasibility of an exercise program in endocrine-treated metastatic breast cancer patients with overweight: protocol for the FEMA study. PMID 40176194 · Pilot Feasibility Stud · 2025-Apr-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
IPD regimen effect on the levels of VEGF and IL-6 in elderly patients with recurrent multiple myeloma. PMID 40788733 · Indian J Cancer · 2025-Apr-01 The study meets most eligibility criteria: it is an oncology, human, randomized trial with drug intervention, time-to-event (PFS) analysis, and original results. However, the explicit trial phase (Phase III/IIIb or Phase II/III) is not confirmed in the available metadata. Therefore, the 'phase3_or_definitive' criterion cannot be set to true, leading to ineligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -